0 5 Human human JJ 6 22 immunodeficiency immunodeficiency NN 23 39 virus-associated virus-associated JJ 40 47 Hodgkin Hodgkin NNP 47 49 ’s 's POS 50 57 disease disease NN 58 65 derives derive VBZ 66 70 from from IN 71 84 post-germinal post-germinal JJ 85 91 center center NN 92 93 B b NN 94 99 cells cell NNS 99 100 . . . 102 107 Human human JJ 108 124 immunodeficiency immunodeficiency NN 125 141 virus-associated virus-associated JJ 142 149 Hodgkin Hodgkin NNP 149 151 ’s 's POS 152 159 disease disease NN 160 161 ( ( ( 161 167 HIV-HD HIV-HD NNP 167 168 ) ) ) 169 177 displays display VBZ 178 185 several several JJ 186 199 peculiarities peculiarity NNS 200 204 when when WRB 205 213 compared compare VBN 214 218 with with IN 219 221 HD HD NNP 222 224 of of IN 225 228 the the DT 229 236 general general JJ 237 247 population population NN 247 248 . . . 249 254 These these DT 255 262 include include VBP 263 281 overrepresentation overrepresentation NN 282 284 of of IN 285 295 clinically clinically RB 296 306 aggressive aggressive JJ 307 317 histologic histologic JJ 318 323 types type NNS 324 327 and and CC 328 336 frequent frequent JJ 337 346 infection infection NN 347 349 of of IN 350 364 Reed-Sternberg Reed-Sternberg NNP 365 366 ( ( ( 366 368 RS RS NNP 368 369 ) ) ) 370 375 cells cell NNS 376 378 by by IN 379 391 Epstein-Barr epstein-barr JJ 392 397 virus virus NN 398 399 ( ( ( 399 402 EBV EBV NNP 402 403 ) ) ) 403 404 . . . 405 413 Recently recently RB 413 414 , , , 415 417 we we PRP 418 422 have have VBP 423 431 reported report VBN 432 436 that that IN 437 440 the the DT 441 453 histogenesis histogenesis NN 454 456 of of IN 457 459 HD HD NNP 460 462 of of IN 463 466 the the DT 467 474 general general JJ 475 485 population population NN 486 489 may may MD 490 492 be be VB 493 501 assessed assess VBN 502 504 by by IN 505 515 monitoring monitor VBG 516 519 the the DT 520 530 expression expression NN 531 538 pattern pattern NN 539 541 of of IN 542 547 BCL-6 BCL-6 NNP 547 548 , , , 549 550 a a DT 551 564 transcription transcription NN 565 571 factor factor NN 572 581 expressed express VBN 582 584 in in IN 585 593 germinal germinal JJ 594 600 center center NN 601 602 ( ( ( 602 604 GC GC NNP 604 605 ) ) ) 606 607 B B NNP 608 613 cells cell NNS 613 614 , , , 615 618 and and CC 619 621 of of IN 622 638 CD138/syndecan-1 cd138/syndecan-1 NN 639 640 ( ( ( 640 645 syn-1 syn-1 NN 645 646 ) ) ) 646 647 , , , 648 649 a a DT 650 662 proteoglycan proteoglycan NN 663 673 associated associate VBN 674 678 with with IN 679 686 post-GC post-gc JJ 686 687 , , , 688 696 terminal terminal JJ 697 703 B-cell b-cell NN 704 719 differentiation differentiation NN 719 720 . . . 721 723 In in IN 724 728 this this DT 729 734 study study NN 734 735 , , , 736 738 we we PRP 739 743 have have VBP 744 751 applied apply VBN 752 757 these these DT 758 761 two two CD 762 769 markers marker NNS 770 772 to to TO 773 776 the the DT 777 782 study study NN 783 785 of of IN 786 792 HIV-HD HIV-HD NNP 793 805 histogenesis histogenesis NN 806 809 and and CC 810 820 correlated correlate VBD 821 826 their their PRP$ 827 837 expression expression NN 838 844 status status NN 845 847 to to TO 848 851 the the DT 852 861 virologic virologic JJ 862 870 features feature NNS 871 873 of of IN 874 878 this this DT 879 886 disease disease NN 886 887 . . . 888 890 We we PRP 891 895 have have VBP 896 901 found find VBN 902 906 that that IN 907 909 RS RS NNP 910 915 cells cell NNS 916 918 of of IN 919 922 all all DT 923 933 histologic histologic JJ 934 944 categories category NNS 945 947 of of IN 948 954 HIV-HD HIV-HD NNP 955 967 consistently consistently RB 968 975 display display VBP 976 979 the the DT 980 997 BCL-6(-)/syn-1(+) bcl-6(-)/syn-1(+) JJ 998 1007 phenotype phenotype NN 1008 1011 and and CC 1012 1016 thus thus RB 1017 1024 reflect reflect VBP 1025 1032 post-GC post-gc JJ 1033 1034 B b NN 1035 1040 cells cell NNS 1040 1041 . . . 1042 1050 Although although IN 1051 1070 BCL-6(-)/syn-1(+)RS bcl-6(-)/syn-1(+)rs JJ 1071 1076 cells cell NNS 1077 1079 of of IN 1080 1086 HIV-HD HIV-HD NNP 1087 1094 express express VBP 1095 1099 CD40 cd40 NN 1099 1100 , , , 1101 1105 they they PRP 1106 1109 are be VBP 1110 1113 not not RB 1114 1124 surrounded surround VBN 1125 1127 by by IN 1128 1132 CD40 cd40 NN 1133 1148 ligand-positive ligand-positive JJ 1149 1150 ( ( ( 1150 1156 CD40L+ cd40l+ JJ 1156 1157 ) ) ) 1158 1166 reactive reactive JJ 1167 1168 T t NN 1169 1180 lymphocytes lymphocyte NNS 1180 1181 , , , 1182 1187 which which WDT 1187 1188 , , , 1189 1191 in in IN 1192 1194 HD HD NNP 1195 1197 of of IN 1198 1201 the the DT 1202 1209 general general JJ 1210 1220 population population NN 1220 1221 , , , 1222 1225 are be VBP 1226 1233 thought think VBN 1234 1236 to to TO 1237 1245 regulate regulate VB 1246 1249 the the DT 1250 1257 disease disease NN 1258 1267 phenotype phenotype NN 1268 1275 through through IN 1276 1286 CD40/CD40L cd40/cd40l NN 1287 1299 interactions interaction NNS 1299 1300 . . . 1301 1311 Conversely conversely RB 1311 1312 , , , 1313 1315 RS RS NNP 1316 1321 cells cell NNS 1322 1324 of of IN 1325 1334 virtually virtually RB 1335 1338 all all DT 1339 1345 HIV-HD HIV-HD NNP 1346 1353 express express VBP 1354 1357 the the DT 1358 1369 EBV-encoded ebv-encoded JJ 1370 1376 latent latent JJ 1377 1385 membrane membrane NN 1386 1393 protein protein NN 1394 1395 1 1 CD 1396 1397 ( ( ( 1397 1401 LMP1 LMP1 NNP 1401 1402 ) ) ) 1402 1403 , , , 1404 1409 which which WDT 1409 1410 , , , 1411 1416 being be VBG 1417 1429 functionally functionally RB 1430 1440 homologous homologous JJ 1441 1443 to to TO 1444 1448 CD40 CD40 NNP 1448 1449 , , , 1450 1453 may may MD 1454 1464 contribute contribute VB 1464 1465 , , , 1466 1468 at at IN 1469 1474 least least JJS 1475 1477 in in IN 1478 1482 part part NN 1482 1483 , , , 1484 1486 to to TO 1487 1490 the the DT 1491 1501 modulation modulation NN 1502 1504 of of IN 1505 1508 the the DT 1509 1515 HIV-HD HIV-HD NNP 1516 1525 phenotype phenotype NN 1525 1526 . . .